Off-label or off-limits?

被引：0
|
作者：
Mark Ratner
Trisha Gura
机构：
[1] Trisha Gura is a Boston-based writer and former Knight fellow.,
来源：
Nature Biotechnology | 2008年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Off-label prescribing is a fundamental fact of life of healthcare systems, but the promotion of off-label uses by drug sponsors is a fundamental sin. Regulators, legislators and drug makers are wrestling to find the right balance.
引用
收藏
页码：867 / 875
页数：8
相关论文
共 50 条
  • [21] The "Off-label" TAVI
    Kornowski, Ran
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2013, 15 (08): : 443 - 444
  • [22] Off-label perils
    不详
    COMPENDIUM ON CONTINUING EDUCATION FOR THE PRACTICING VETERINARIAN, 2004, 26 (11): : 834 - 834
  • [23] Off-label prescribing
    Gazarian, Madlen
    Morris, Steve
    MEDICAL JOURNAL OF AUSTRALIA, 2014, 200 (11) : 637 - 637
  • [24] Off-label prescribing
    Seale, J. Paul
    MEDICAL JOURNAL OF AUSTRALIA, 2014, 200 (02) : 65 - 65
  • [25] Off-label therapy
    Myers, Gary
    NEW SCIENTIST, 2014, 223 (2983) : 29 - 29
  • [26] "Off-label" deworming
    Boissevain, Iaira
    TIJDSCHRIFT VOOR DIERGENEESKUNDE, 2009, 134 (21) : 897 - 897
  • [27] Going off-label
    Lucas, Catherine
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (08): : 556 - 556
  • [28] Off-label prescribing
    Kelly, Maria
    Gazarian, Madlen
    McPhee, John
    AUSTRALIAN PRESCRIBER, 2005, 28 (01) : 7 - 7
  • [29] OFF-LABEL PREEMPTION
    Simon, David A.
    WISCONSIN LAW REVIEW, 2024, (03) : 1080 - 1147
  • [30] A status for off-label
    Derrien, Elisa
    ACTUALITES PHARMACEUTIQUES, 2019, 58 (582): : 6 - 6
12345